UBS Group
FHTX icon

UBS Group’s Foghorn Therapeutics FHTX Stock Holding History

UBS Group’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.8K Sell
11,231
-64,604
-85% -$287K ﹤0.01% 7515
2026
Q1 		$362K Buy
75,835
+51,330
+209% +$282K ﹤0.01% 6301
2025
Q4 		$132K Sell
24,505
-10,339
-30% -$46.9K ﹤0.01% 6770
2025
Q3 		$170K Sell
34,844
-7,956
-19% -$42.2K ﹤0.01% 6767
2025
Q2 		$201K Sell
42,800
-3,558
-8% -$14.9K ﹤0.01% 6718
2025
Q1 		$169K Buy
46,358
+8,863
+24% +$40.4K ﹤0.01% 6653
2024
Q4 		$177K Buy
37,495
+25,565
+214% +$186K ﹤0.01% 6527
2024
Q3 		$111K Buy
11,930
+4,239
+55% +$30.7K ﹤0.01% 6279
2024
Q2 		$44.2K Sell
7,691
-12,683
-62% -$75.5K ﹤0.01% 6783
2024
Q1 		$137K Sell
20,374
-3,007
-13% -$16.7K ﹤0.01% 6082
2023
Q4 		$151K Buy
23,381
+12,945
+124% +$55.8K ﹤0.01% 5946
2023
Q3 		$52.2K Sell
10,436
-1,895
-15% -$14.6K ﹤0.01% 6267
2023
Q2 		$86.8K Buy
12,331
+4,672
+61% +$32.7K ﹤0.01% 6125
2023
Q1 		$47.5K Buy
7,659
+2,612
+52% +$17.1K ﹤0.01% 6496
2022
Q4 		$32.2K Buy
+5,047
New +$38.1K ﹤0.01% 7165
2022
Q2 		– Sell
-2,923
Closed -$45K – 10496
2022
Q1 		$45K Sell
2,923
-3,970
-58% -$54.5K ﹤0.01% 6600
2021
Q4 		$158K Buy
+6,893
New +$99.1K ﹤0.01% 5895
2021
Q2 		– Sell
-2,136
Closed -$28K – 9495
2021
Q1 		$28K Sell
2,136
-112
-5% -$1.83K ﹤0.01% 7063
2020
Q4 		$46K Buy
+2,248
New +$43.1K ﹤0.01% 6258

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS Group's FHTX Position: Q2 2026 in Review

UBS Group reduced its Foghorn Therapeutics (FHTX) stake by 85% in Q2 2026, selling an estimated $287K and leaving 11,231 shares worth $54.8K. The position accounts for ﹤0.01% of the portfolio, ranked #7515.

UBS Group first reported a position in FHTX in Q4 2020 and has held it in 19 quarters since. The position peaked at $362K in Q1 2026. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • UBS Group held 11,231 shares of Foghorn Therapeutics worth $54.8K as of Q2 2026.
  • UBS Group sold 64,604 Foghorn Therapeutics shares in Q2 2026, an estimated $287K.
  • Foghorn Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7515 holding.
  • UBS Group first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • UBS Group's Foghorn Therapeutics position peaked at $362K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.